BDF Gestion Makes New $1.63 Million Investment in DexCom, Inc. $DXCM

BDF Gestion acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 18,890 shares of the medical device company’s stock, valued at approximately $1,630,000.

Several other large investors also recently modified their holdings of the company. USA Financial Formulas bought a new position in DexCom in the third quarter valued at about $747,000. TD Waterhouse Canada Inc. grew its stake in shares of DexCom by 17.4% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 7,873 shares of the medical device company’s stock valued at $680,000 after purchasing an additional 1,169 shares during the period. V Square Quantitative Management LLC increased its position in shares of DexCom by 8.6% during the 3rd quarter. V Square Quantitative Management LLC now owns 4,301 shares of the medical device company’s stock valued at $371,000 after purchasing an additional 339 shares during the last quarter. Curated Wealth Partners LLC purchased a new stake in shares of DexCom during the 3rd quarter valued at about $333,000. Finally, Mather Group LLC. increased its position in shares of DexCom by 27.7% during the 3rd quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock valued at $49,000 after purchasing an additional 122 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on DXCM shares. Robert W. Baird set a $105.00 price objective on shares of DexCom in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft assumed coverage on shares of DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price for the company. Raymond James Financial reiterated a “strong-buy” rating and issued a $94.00 price target on shares of DexCom in a research report on Friday, July 31st. Mizuho set a $100.00 price target on shares of DexCom in a research note on Tuesday, October 13th. Finally, BTIG Research lifted their price target on shares of DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $92.43.

DexCom Stock Performance

Shares of NASDAQ DXCM traded down $0.22 during trading on Monday, hitting $85.82. The company had a trading volume of 775,143 shares, compared to its average volume of 4,962,913. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The firm has a market capitalization of $32.39 billion, a P/E ratio of 33.97, a price-to-earnings-growth ratio of 1.44 and a beta of 1.48. The stock has a 50 day simple moving average of $87.61 and a 200 day simple moving average of $75.96.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The firm’s revenue was up 13.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.48 EPS. As a group, analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current year.

Insider Buying and Selling at DexCom

In related news, Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $549,537.56. Following the transaction, the director owned 29,293 shares in the company, valued at approximately $2,461,783.72. The trade was a 18.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme Sylvain sold 3,638 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the completion of the transaction, the executive vice president directly owned 146,828 shares of the company’s stock, valued at $12,226,367.56. This represents a 2.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 22,557 shares of company stock valued at $1,903,857. 0.28% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.